U. Rehwald

Articles by U. Rehwald

Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia

ByH. Schulz,S. K. Klein,U. Rehwald,Maximilian F. Reiser, MD,S. Ibach,W. E. Aulitzky,M. Hensel,M. Herold,D. Huhn,U. Knauf,Michael Hallek, MDDirector,Volker Diehl, MD, PhD,Andreas Engert, MD, PhD

March 1st 2002

This phase II trial investigated the safety and efficacy of a combined-modality treatment with rituximab (Rituxan) and fludarabine (Fludara) in patients with fludarabine- and anthracycline-naive chronic lymphocytic lymphoma (CLL).

Latest Updated Articles

Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia
Published: March 1st 2002 | Updated:

U. Rehwald

Articles by U. Rehwald

Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma